

Yi Zhu<sup>1</sup>, Amanda G. Lobato<sup>1,2</sup>, Adriana Rebelo<sup>3</sup>, Tijana Canic<sup>4</sup>, Sheyum Syed<sup>4</sup>, Riccardo Perfetti<sup>5</sup>, Shoshana Shendelman<sup>5</sup>, Stephan Züchner<sup>3</sup>, R. Grace Zhai<sup>1</sup>

<sup>1</sup>Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, FL

<sup>2</sup>Graduate Program in Human Genetics and Genomics, University of Miami Miller School of Medicine, Miami, FL


<sup>3</sup>Dr. John T. Macdonald Foundation Department of Human Genetics and John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, FL

<sup>4</sup>Department of Physics, University of Miami, Coral Gables, FL


<sup>5</sup>R&D Development, Applied Therapeutics, New York, NY

## Introduction

Sorbitol dehydrogenase (SORD) deficiency has been identified as the most frequent autosomal recessive form of hereditary neuropathy, affecting roughly 10,000 patients worldwide. Loss of SORD causes high sorbitol levels in cells due to the inability to convert sorbitol to fructose in the two-step polyol pathway, leading to neurodegeneration. However, underlying mechanisms of sorbitol-induced neurodegeneration have not been fully elucidated.



## AT-007 improves locomotor activity




## Method


A *Drosophila* model of SORD deficiency was characterized by locomotor assay and brain imaging. Reactive oxygen species (ROS) staining in the brain and muscle was performed to understand the pathological changes at the molecular level. To reduce sorbitol accumulation by inhibiting conversion from glucose, a next-generation central nervous system (CNS) penetrant aldose reductase inhibitor (ARI) developed by Applied Therapeutics, Inc, named AT-007, was applied to patient-derived fibroblasts and flies. Sorbitol levels in cells and fly brains were measured, and neurological phenotypes of flies were analyzed.

## AT-007 reduces sorbitol in patient cells


Structure		Dosing	Once daily
IC <sub>50</sub>	0.10 nM	Formulation	Liquid Suspension
Half-life	~15 hours	CNS Penetrant	Yes




## AT-007 rescues mitochondrial dysfunction



## AT-007 alleviates synaptic degeneration



## AT-007 reduces ROS accumulation



## Summary

- AT-007 significantly reduced sorbitol levels in patient-derived fibroblasts and motor neurons.
- AT-007 feeding significantly improved locomotor activity, mitigated synaptic degeneration, rescued mitochondrial dysfunction, and reduced ROS levels.
- Our findings establish the underlying disease pathogenesis and provide a potential treatment strategy for patients with SORD deficiency.

## References

- Sharma, G., et al. (2021). "Genetic neuropathy due to impairments in mitochondrial dynamics." *Biology (Basel)* 10(4).
- Cortese, A., et al. (2020). "Biallelic mutations in SORD cause a common and potentially treatable hereditary neuropathy with implications for diabetes." *Nat Genet* 52(5): 473-481.
- Pichaud, N., et al. (2019). "Age dependent dysfunction of mitochondrial and ROS metabolism induced by mitonuclear mismatch." *Front Genet* 10: 130.
- Yan, L. J. (2018). "Redox imbalance stress in diabetes mellitus: Role of the polyol pathway." *Animal Model Exp Med* 1(1): 7-13
- Areti, A., et al. (2016). "Potential therapeutic benefits of maintaining mitochondrial health in peripheral neuropathies." *Current Neuropharmacology* 14: 593-609.
- Pezier, A. P., et al. (2016). "Shaking B Mediates Synaptic Coupling between Auditory Sensory Neurons and the Giant Fiber of *Drosophila melanogaster*." *PLoS One* 11(4): e0152211.
- Manchester Fly Facility. (2015). *droso4schools*: Online resources for school lessons using the fruit fly *Drosophila*.
- Owusu-Ansah, E., et al. (2013). "Muscle mitohormesis promotes longevity via systemic repression of insulin signaling." *Cell* 155(3): 699-712.